Health & science
Clinical Trial Results One-Pager
Report a trial's results: endpoints, response and safety. Research teams use it for readouts.
Make one freeFree, no account needed
What’s on It
- Headline numbersThe Primary Endpoint
- Line chart over timeResponse Over Time
- Key pointsWhat the Data Says
- Before and after chartSecondary Endpoints, Baseline to Week 16
Sample One-Pager. Company and figures are made up.
Phase II Readout: RVX-311
Moderate-to-severe eczema · 312 patients · 16 weeks
The Primary Endpoint
EASI-75 at week 16
68%
+29 pts
vs 39% on placebo
Primary endpoint
p<0.001
Powered at 90%
Patients randomised
312
3 arms, 24 sites
Discontinued
4.1%
-2.3 pts
vs 6.4% on placebo
Response Over Time
RVX-311 300mgPlacebo
What the Data Says
Separation from placebo is clear by week 4 and widens to week 16.
No serious adverse events attributed to study drug.
Effect holds in the 94 patients who failed a biologic before.
Secondary Endpoints, Baseline to Week 16
BaselineWeek 16
Peak itch (NRS)2.6 score-4.8
Sleep loss (NRS)2.2 score-3.9
Quality of life (DLQI)4.9 score-9.9
Affected body area (%)12 score-29
Make One from Your File
Drop in a PDF, Word or PowerPoint file. Get your One-Pager in a minute or two.
Make one free